The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints
- PMID: 32166761
- PMCID: PMC7240768
- DOI: 10.1111/1475-6773.13282
The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints
Abstract
Objective: To determine the effect of Medicaid expansion on the use of opioid agonist treatment for opioid use disorder (OUD) and to examine heterogeneous effects by provider supply and Medicaid acceptance rates.
Data sources: Yearly state-level data on methadone dispensed from opioid treatment programs (OTPs), buprenorphine dispensed from OTPs and pharmacies, number of OTPs and buprenorphine-waivered providers, and percent of OTPs and physicians accepting Medicaid.
Study design: This study used difference-in-differences models to examine the effect of Medicaid expansion on the amount of methadone and buprenorphine dispensed in states between 2006 and 2017. Interaction terms were used to estimate heterogeneous effects. Sensitivity analyses included testing the association of outcomes with Medicaid enrollment and state insurance rates.
Principal findings: The estimated effects of Medicaid expansion on buprenorphine and methadone dispensed were positive but imprecise, meaning we could not rule out negative or null effects of expansion. The estimated associations between state insurance rates and dispensed methadone and buprenorphine were centered near zero, suggesting that improvements in health coverage may not have increased OUD treatment use. The effect of Medicaid expansion was larger in the states with the most waivered providers compared to states with the fewest waivered providers. In the states with the most waivered providers, the average estimated effect of expansion on buprenorphine dispensed was 12 kg/y, enough to treat about 7500 individuals. We did not find evidence that the effect of expansion was consistently modified by OTP concentration, OTP Medicaid acceptance, or physician Medicaid acceptance.
Conclusions: Gains in health coverage may not be sufficient to increase OUD treatment, even in the context of high treatment need. Provider capacity likely limited Medicaid expansion's effect on buprenorphine dispensed. Policies to increase buprenorphine providers, such as ending the waiver requirement, may be needed to ensure coverage gains translate to treatment access.
Keywords: Medicaid expansion; buprenorphine; methadone; opioid use disorder.
© Health Research and Educational Trust.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7240768/bin/HESR-55-383-g001.gif)
Similar articles
-
Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.Subst Abus. 2019;40(3):356-362. doi: 10.1080/08897077.2018.1488336. Epub 2018 Oct 9. Subst Abus. 2019. PMID: 29949454 Free PMC article.
-
Supply of buprenorphine waivered physicians: the influence of state policies.J Subst Abuse Treat. 2015 Jan;48(1):104-11. doi: 10.1016/j.jsat.2014.07.010. Epub 2014 Aug 2. J Subst Abuse Treat. 2015. PMID: 25218919 Free PMC article.
-
Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.Milbank Q. 2015 Sep;93(3):561-83. doi: 10.1111/1468-0009.12137. Milbank Q. 2015. PMID: 26350930 Free PMC article.
-
Buprenorphine in the United States: Motives for abuse, misuse, and diversion.J Subst Abuse Treat. 2019 Sep;104:148-157. doi: 10.1016/j.jsat.2019.07.005. Epub 2019 Jul 12. J Subst Abuse Treat. 2019. PMID: 31370979 Review.
-
Use and misuse of opioid agonists in opioid addiction.Cleve Clin J Med. 2017 May;84(5):377-384. doi: 10.3949/ccjm.84a.16091. Cleve Clin J Med. 2017. PMID: 28530896 Review.
Cited by
-
Association of Medicaid expansion with health insurance, unmet need for medical care and substance use disorder treatment among people who inject drugs in 13 US states.Addiction. 2024 Mar;119(3):582-592. doi: 10.1111/add.16383. Epub 2023 Dec 5. Addiction. 2024. PMID: 38053235
-
National Trends in Buprenorphine Treatment for Opioid Use Disorder From 2007 to 2018.Subst Abus. 2023 Jul;44(3):154-163. doi: 10.1177/08897077231179576. Epub 2023 Jun 6. Subst Abus. 2023. PMID: 37278310 Free PMC article.
-
State Policy and the Breadth of Buprenorphine-Prescriber Networks in Medicaid Managed Care.Med Care Res Rev. 2023 Aug;80(4):423-432. doi: 10.1177/10775587231167514. Epub 2023 Apr 21. Med Care Res Rev. 2023. PMID: 37083043
-
Medicaid Managed Care: Access To Primary Care Providers Who Prescribe Buprenorphine.Health Aff (Millwood). 2022 Jun;41(6):901-910. doi: 10.1377/hlthaff.2021.01719. Health Aff (Millwood). 2022. PMID: 35666962 Free PMC article.
-
The effect of Medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States.Drug Alcohol Depend. 2022 Mar 1;232:109336. doi: 10.1016/j.drugalcdep.2022.109336. Epub 2022 Jan 29. Drug Alcohol Depend. 2022. PMID: 35123365 Free PMC article.
References
-
- Ahmad F, Rossen L, Spencer M, Warner M, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics; Published 2018. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. Accessed May 22, 2019.
-
- Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence In: Mattick RP, ed. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2014:1‐69.
-
- Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication‐assisted therapies — tackling the opioid‐overdose epidemic. N Engl J Med. 2014;370(22):2063‐2066. - PubMed
-
- Stein BD, Gordon AJ, Sorbero M, Dick AW, Schuster J, Farmer C. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: Recent service utilization trends in the use of buprenorphine and methadone. Drug Alcohol Depend. 2012;123(1‐3):72‐78. - PubMed
-
- Beronio K, Glied S, Frank R. How the Affordable Care Act and mental health parity and addiction equity act greatly expand coverage of behavioral health care. J Behav Heal Serv Res. 2014;41(4):410‐428. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical